Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610618-22-000048
Filing Date
2022-06-24
Accepted
2022-06-24 16:29:20
Documents
1
Period of Report
2022-06-22

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_165610254645500.html 4  
1 FORM 4 wf-form4_165610254645500.xml 4 3920
  Complete submission text file 0001610618-22-000048.txt   5439
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CIDARA THERAPEUTICS, INC. 6310 NANCY RIDGE DR STE 101 CA 92121
Business Address
Canale-Theakston Carin (Reporting) CIK: 0001841613 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36912 | Film No.: 221040460